This segment focuses on the research, development, and clinical trials of therapeutics for Alcohol Use Disorder (AUD). The lead product, AD04, is a selective serotonin-3 antagonist currently in Phase 3 clinical trials. Research and development activities include optimizing study designs, analyzing clinical data, and securing manufacturing agreements. The technology used involves understanding the genetic basis of addiction and developing precision medicine approaches. The therapeutic area is AUD, aiming to reduce alcohol consumption and improve patient outcomes. Market positioning is centered on providing a novel treatment option for AUD, with a focus on genotype-specific treatments. Future opportunities include expanding the application of AD04 and developing additional therapies for addiction. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships include collaborations with manufacturing partners like Cambrex and Thermo Fisher Scientific.

This segment encompasses the research and development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company is exploring various therapeutic approaches to address unmet medical needs beyond AUD. Research and development activities include preclinical studies, drug discovery, and exploring new therapeutic targets. The technologies and methodologies employed involve identifying and validating potential drug candidates, conducting preclinical studies, and designing clinical trials. The therapeutic areas covered include non-opioid pain management and other undisclosed diseases and disorders. The patient impact aims to provide effective and safe treatments for pain and other conditions. Market positioning involves identifying and targeting specific patient populations with high unmet needs. Future opportunities include expanding the pipeline with new drug candidates and exploring strategic partnerships. Regulatory and clinical aspects involve navigating the regulatory pathways for new drug approvals. This segment is focused on diversifying the company's portfolio and addressing a broader range of medical conditions.